pH-Sensitive O6-Benzylguanosine Polymer Modified Magnetic Nanoparticles for Treatment of Glioblastomas

详细信息    查看全文

• 作者：Zachary R. Stephen ; Rachel N. Gebhart ; Mike Jeon ; Allison A. Blair ; Richard G. Ellenbogen ; John R. Silber ; Miqin Zhang
• 刊名：Bioconjugate Chemistry
• 出版年：2017
• 出版时间：January 18, 2017
• 年：2017
• 卷：28
• 期：1
• 页码：194-202
• 全文大小：497K
• ISSN：1520-4812

文摘

Nanoparticle-mediated delivery of chemotherapeutics has demonstrated potential in improving anticancer efficacy by increasing serum half-life and providing tissue specificity and controlled drug release to improve biodistribution of hydrophobic chemotherapeutics. However, suboptimal drug loading, particularly for solid core nanoparticles (NPs), remains a challenge that limits their clinical application. In this study we formulated a NP coated with a pH-sensitive polymer of O⁶-methylguanine-DNA methyltransferase (MGMT) inhibitor analog, dialdehyde modified O⁶-benzylguanosine (DABGS) to achieve high drug loading, and polyethylene glycol (PEG) to ameliorate water solubility and maintain NP stability. The base nanovector consists of an iron oxide core (9 nm) coated with hydrazide functionalized PEG (IOPH). DABGS and PEG-dihydrazide were polymerized on the iron oxide nanoparticle surface (IOPH-pBGS) through acid-labile hydrazone bonds utilizing a rapid, freeze–thaw catalysis approach. DABGS polymerization was confirmed by FTIR and quantitated by UV–vis spectroscopy. IOPH-pBGS demonstrated excellent drug loading of 33.4 ± 5.1% by weight while maintaining small size (36.5 ± 1.8 nm). Drug release was monitored at biologically relevant pHs and demonstrated pH dependent release with maximum release at pH 5.5 (intracellular conditions), and minimal release at physiological pH (7.4). IOPH-pBGS significantly suppressed activity of MGMT and potentiated Temozolomide (TMZ) toxicity in vitro, demonstrating potential as a new treatment option for glioblastomas (GBMs).